AstraZeneca's Dapagliflozin tablets get DCGI nod for patients with chronic kidney disease

The company has "received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the DCGI for Dapagliflozin tablets 10 mg," AstraZeneca Pharma India said in a filing to BSE.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/36LXBCe
via IFTTT